ELIQUIS (apixaban): Simple dosing for stroke prevention in NVAF, with or without food
- In the ARISTOTLE clinical trial, the majority of patients were on 5 mg BD (95.3%, n = 8,692/9,120)2*
- Liver function testing should be performed prior to initiating ELIQUIS1
ELIQUIS can be taken with or without food1
Missed dose: if a dose is missed, the patient should take ELIQUIS immediately and then continue with twice-daily intake as before1
Please click here to access the ELIQUIS Patient Information Leaflet.
* In the ARISTOTLE trial, a total of 18,201 patients with NVAF and one risk factor for stroke and mean CHADS2 score of 2.1 were randomised to ELIQUIS 5mg BD (or 2.5 mg BD in selected patients [4.7%]) or warfarin adjusted to target INR range range 2.0–3.0. Stroke or systemic embolism was the primary efficacy endpoint of the ARISTOTLE trial (hameorrhagic stroke and ischaemic or undetermined stroke were components of stroke) and major bleeding defined per International Society on Thrombosis and Heamostasis (ISTH) criteria were the primary endpoint. Efficacy analyses based on the intention-to-treat population. Safety analyses based on patients who had at least one dose of study drug.2
BD = Twice Daily CHADS2 = Congestive heart failure, Hypertension, Age ≥75, Diabetes, Stroke (doubled) CrCl = Creatine Clearance INR = International Normalised Ratio NVAF = Non-Valvular Atrial Fibrillation
References:
- ELIQUIS® (apixaban) Summary of Product Characteristics.
- Granger CB et al. N Engl J Med 2011; 365: 981–992.